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Abstract
Background: Cognitive impairment is common in haemodialysis (HD) patients and is associated independently
with depression and mortality. This association is poorly understood, and no intervention is proven to slow
cognitive decline. There is evidence that cooler dialysis fluid (dialysate) may slow white matter changes in the brain,
but no study has investigated the effect of cooler dialysate on cognition. This study addresses whether cooler
dialysate can prevent the decline in cognition and improve quality of life (QOL) in HD patients.
Methods: This is a multi-site prospective randomised, double-blinded feasibility trial. Setting: Four HD units in the
UK. Participants and interventions: Ninety HD patients randomised (1:1) to standard care (dialysate temperature
36.5 °C) or intervention (dialysate temperature 35 °C) for 12 months. Primary outcome measure: Change in cognition
using the Montreal Cognitive Assessment (MoCA). Secondary outcome measures: Recruitment and attrition rates,
reasons for non-recruitment, frequency of intradialytic hypotension, depressive symptom scores, patient and carers
burden, a detailed computerised cognitive test and QOL assessments. Analysis: mixed method approach, utilising
measurement of cognition, questionnaires, physiological measurements and semi-structured interviews.
(Continued on next page)
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: indranil.dasgupta@uhb.nhs.uk
1Renal Unit, Heartlands Hospital, Bordesley Green East, Birmingham B9 5SS,
UK
2Warwick Medical School, University of Warwick, Coventry, UK
Full list of author information is available at the end of the article
Dasgupta et al. Trials          (2020) 21:820 
https://doi.org/10.1186/s13063-020-04725-0
(Continued from previous page)
Discussion: The results of this feasibility trial will inform the design of a future adequately powered substantive trial
investigating the effect of dialysate cooling on prevention and/or slowing in cognitive decline in patients
undergoing haemodialysis using a computerised battery of neuro-cognitive tests. The main hypothesis that would
be tested in this future trial is that patients treated with regular conventional haemodialysis will have a lesser
decline in cognitive function and a better quality of life over 1 year by using cooler dialysis fluid at 35 °C, versus a
standard dialysis fluid temperature of 36.5 °C. This also should reflect in improvements in their abilities for activities
of daily living and therefore reduce carers’ burden. If successful, the treatment could be universally applied at no
extra cost.
Trial registration: ClinicalTrials.gov NCT03645733. Registered retrospectively on 24 August 2018.
Keywords: Cognition, Cognitive function, Cold temperature, Haemodialysis, Haemodialysis solutions, Randomised
controlled trial
Background
Increasing severity of chronic kidney disease (CKD) is asso-
ciated with a gradual increase in prevalence of cognitive im-
pairment [1, 2] independent of vascular risk factors [3].
Different diagnostic methods influence the definition and
incidence of cognitive impairment, but recent reviews sug-
gest the presence of at least moderate cognitive impairment
in 30–70% of haemodialysis (HD) patients [4–6]. Cognitive
impairment in HD patients is associated independently
with higher rates of depression and mortality [4, 7], al-
though this association is likely complex and poorly under-
stood. Severe depression can even mimic cognitive
impairment making it important to measure depression
rates in studies of cognitive impairment to understand the
interaction. Traditional atherosclerotic risk factors [7] can-
not entirely account for the excess risk of cognitive impair-
ment [8]. Multiple HD specific factors including oxidative
stress, malnutrition and inflammation are implicated [9].
The process of HD does not remove toxins as efficiently as
the native kidney and accumulation of several neurotoxins
[10] may also act to reduce brain perfusion and comprom-
ise blood-brain barrier integrity [11]. The process of HD in-
volves cycles of removing varying volumes of fluid,
electrolytes and toxins that accumulate between treatments.
Intradialytic hypotension is common affecting 30–40% of
treatments and is associated with at least a 30% increase in
mortality and reduced quality-of-life (QOL) [12]. Left ven-
tricular hypertrophy and aortic stiffness are seen in most
HD patients and further lower diastolic coronary perfusion.
The result is that HD might be seen as a process that fre-
quently involves repeated ischemic insults to the brain and
other organs [13–15]. These dynamic changes in blood
pressure (BP) and perfusion might be associated with al-
tered cognition, but supporting data are sparse and conflict-
ing, possibly reflecting differences in study design such as
different methods and timings of cognitive assessment. Sev-
eral small studies show cognition is best immediately before
HD, becomes worse during HD and then improves the day
after with a possible link to acute fluid removal [16, 17].
Absence of intradialytic hypotension is emerging as a novel
treatment goal and it is plausible that preventing intradialy-
tic hypotension might prevent intradialytic brain ischemia
and slow the development of cognitive impairment in HD
patients [18]. One method that may prevent intradialytic
hypotension is to increase treatment time or frequency to
allow a slower rate of fluid removal [19]. A preliminary re-
peated measures study of 12 patients showed extended
overnight HD was associated with improved cognition
measured by a battery of neuropsychological tests [20].
These data are encouraging but come at the expense of in-
creased treatment complications, cost and are currently not
feasible in most centres in the UK and worldwide. The use
of cooler dialysate (34–35 °C) to prevent intradialytic
hypotension was first described in 1981 [21], but remains
underused because of perceptions about thermal symptoms
[22–24]. Cooler dialysate is thought to prevent intradialytic
hypotension by preventing a rise in core temperature and
subsequent systemic vasodilation [25]. A recent systematic
review showed that compared with standard temperature
dialysis, cooler dialysis reduced the event rate of intradialy-
tic hypotension by 70% (95% CI, 49–89%) [24]. A recent
pilot clinical trial in 38 patients showed lower temperature
of dialysis fluid applied for one year prevented worsening of
baseline ischaemic brain white matter change through
ameliorating haemodynamic instability [26, 27]. A trial also
reported cooler dialysis fluid improved cardiac structure
and function [28]. While these results show the potential
for dialysate cooling as a cardioprotective and neuroprotec-
tive treatment, the effects of cooler dialysate on cognition,
QOL and illness burden remain unknown. There is also lit-
tle information about how cooler dialysis fluid is tolerated.
The current low usage of cooler dialysate in the UK affords
an opportunity to definitively test this simple modification
to HD as a potential intervention to prevent cognitive im-
pairment and increase QOL. There remain several uncer-
tainties around study design of a definitive trial of cooler
dialysate and cognitive impairment; hence, there is a need
to assess this formally in a feasibility study.
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Methods
We aim to perform a feasibility trial that will inform the
development of a definitive, fully powered, randomised,
controlled clinical trial that would examine the efficacy
of cooler dialysis fluid in reducing cognitive decline in
patients receiving HD for End-Stage Kidney Disease
(ESKD). The main hypothesis that would be tested in
this future trial is that patients treated with regular con-
ventional HD will have a reduced decline in cognition
and a better QOL over 1 year by using cooler dialysis
fluid at 35 °C, versus patients treated using a standard
dialysis fluid temperature of 36.5 °C.
Primary objective
The primary objective is to test the feasibility of the in-
vestigation of lower temperatures of dialysis fluid in pre-
venting the decline in cognitive function and improve
the quality of life in HD patients.
Secondary objectives
1) To provide an estimate of the variability in the
outcome measures for the cooled dialysis and
standard treatment arms, to inform a future,
adequately powered, definitive trial.
2) To measure the frequency of intradialytic
hypotension as an explanatory outcome.
3) To measure recruitment and attrition rates to
inform the design of a larger clinical trial.
4) To record reasons for non-recruitment and study at-
trition to inform the design of a larger clinical trial.
5) To measure baseline levels of depression in the
targeted population to inform estimates of
exclusion rates for participants with depressive
pseudo cognitive impairment from the future trial.
6) To assess the burden of study-related interventions
and assessments on patients and carers.
7) To assess the administration, suitability and adherence
of the chosen method for assessment of cognition in
patients, especially in those from ethnic minorities.
8) To assess the administration and suitability of the
chosen QOL scales and activities of daily living in
HD participants.
9) To assess the administration and suitability of the
chosen method for measuring carers’ burden in this
group.
The protocol will be considered viable for a definitive
RCT without modification if the following outcomes are
met:
1) Recruitment rates of at least 50% of eligible
patients;
2) Attrition rate of < 20% by 6 months;
3) Compliance rate of 60% to trial.
If these outcomes are not met, the protocol will be
modified in light of the study’s findings.
We used the Standard Protocol Items: Recommenda-
tions for Interventional Trials (SPIRIT) checklist when
writing our report [29].
Study design
The schedule of events is summarised in Fig. 1 and
Table 1. The study is a multi-site, prospective, rando-
mised, double-blinded, controlled, feasibility trial [30].
Study setting and population
Patients will be recruited through the renal clinics at
four HD units in the United Kingdom at Birmingham
Heartlands Hospital, Runcorn Road Renal Unit, Solihull
Hospital and Castle Vale Renal Unit. All these HD units
are under the collective organisation of the University
Hospitals Birmingham NHS Foundation Trust. The
study aims to recruit 90 patients allocating 45 patients in
the intervention and 45 patients in the control group.
Suitable patients will be identified by the direct care
team. The care team will speak with the suitable patients
to see if they are happy to have their details passed on to
the research team for further discussion. If the patient
agrees, the research team will contact the patient and
determine eligibility. Suitable patients will be identified
through searching records in the four participating units.
An information pack will be given to the patient (see
Additional file 1), who will be given 24 h to read the in-
formation and ask any questions they may have. The re-
search team will then contact the patient, in a pre-
agreed manner (i.e. next clinic visit, via telephone) to see
if they have any further questions or would like to par-
ticipate in the study. If they would like to participate in
the study they will arrange to meet and complete the
consent form (see Additional file 2).
Inclusion criteria
1. Aged 18 years or greater.
2. Receiving HD three times per week for ESKD, for at
least 3 months.
3. Having proven mental capacity to understand the
study and give informed consent.
Exclusion criteria
1. Established diagnosis of dementia in a memory
clinic or specialised service.
2. Receiving acetylcholinesterase inhibitors.
3. Receiving antipsychotic or antidepressants unless
stable on treatment for at least 6 weeks.
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4. Current participation in a study of an
investigational medicinal product.
5. Inter-current infection.
6. An operation date for a living donor kidney
transplant within the period of the trial.
7. Patients expected to survive less than 1 year
according to the treating nephrologist.
8. Patients prone to intra-dialytic hypotension or car-
diovascular instability during HD according to the
treating nephrologist.
9. Patients who are currently taking triptans,
dopamine antagonists, tramadol, sedative and
opioid analgesics.
10. Patients who have a known diagnosis or have other
psychiatric conditions, including severe depression,
bipolar affective disorder, severe anxiety, panic
disorder, substance misuse or psychosis.
11. Currently involved in another intervention study.
Inclusion criteria (carers)
1. Adult above the age of 18.
2. Consents to take part in the study.
3. Speaks English.
Exclusion criteria (carers)
1. Not in regular contact with the patient.
2. Any apparent personal or psychological conflicts
with the patient that could skew their feedback as
judged by the research team.
3. Evidence for very poor physical health that would
prevent them from completing the study.
Participant withdrawal
Participants are free to withdraw at any time and this will
not affect their future care. They will be asked if they wish
to withdraw completely, and have all data removed from
the study, or just from the point of withdrawal.
Randomisation and concurrent treatments
Currently in the UK, temperatures between 35 °C and
37 °C are empirically used in dialysis; however, the best
temperature is not known and may be differentially tol-
erated depending on the patients’ own core temperature
[39]. International clinical guidelines recommend a mini-
mum temperature for the dialysate of 35 °C mainly for
cardiovascular stability [40, 41]. All consenting partici-
pants eligible for inclusion will be randomised on a 1:1
Fig. 1 Study flow chart
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basis to the control group dialysate temperature of 36.5 °C
for 12months or cooled dialysate temperature of 35 °C for
12months. Randomisation will be stratified by age group
using a secure internet-based system that concealed treat-
ment allocations (Sealed Envelope, London, UK). The ran-
domisation software (https://www.sealedenvelope.com/
simple-randomiser/v1/trials/e-checked) contains the ran-
domisation sequence that is not available to the research
personnel (unless blinding needs to be broken in case of
SAEs). The software requires the details of the patients to
be entered before the randomisation arm is revealed
thereby maintaining concealment of the allocation. This
process will be performed by a research nurse who will
not be involved with any other part of the study.
Study interventions
Patients will be randomised to one of two groups: the inter-
vention and the control group. Both groups will have a pre-
study run-in phase of 2 weeks to establish pre-dialysis
temperature with a tympanic thermometer taken at each
session. The control group will then use the standard di-
alysate temperature of 36.5 °C. The intervention group will
start off using a dialysate temperature of 36 °C. Thereafter,
the dialysate temperature will be reduced every 2 weeks by
0.5 °C until a temperature of 35 °C is reached. Patients who
fail to tolerate the temperature of 35 °C, the lowest toler-
ated temperature, will be carried over to the end of the
study. Tympanic and dialysate temperature will be recorded
at every session regardless of study group to aid monitoring
of protocol adherence and allow an interim analysis of pa-
tient’s temperatures to ensure a clear temperature separ-
ation of the study groups. The research nurse will assess
temperature tolerability every 2 weeks using a Tolerability
of Low Temperature Dialysis Questionnaire for the first 6
weeks. The patients will not be informed to their group
allocation nor the temperature setting of the machine to
enable unbiased comparison of the tolerability of the inter-
vention. The investigators carrying out cognitive assess-
ment and study related procedures will also be blinded to
their group allocation. The clinical nursing staff must be
unblinded to deliver the intervention, but any temperature
display on the machine will be concealed from the patients.
Any patient from the control group and intervention group
complaining of feeling cold during haemodialysis session
will be provided with an extra blanket to aid tolerance and
improve comfort. But if patient could not tolerate the lower
temperature to the point that they felt they could terminate
the session, the temperature will be increased back to the
Table 1 Study schedule of data collection and assessments
Baseline (O month) 6 months 12months
Consent X
Randomisation X
Baseline data (defined) X
Cognitive function:
Montreal Cognitive Assessment [31] X X X
Cogstate [32] X X X
Confusion Assessment Method [33] X X X
Tolerability of Low Temperature Dialysis Questionnaire Every 2 weeks for the first 6 weeks
Activities of daily living:
Assessment of QoL [34] X X X
Bristol Activities of Daily Living Scale [35] X X X
Carer burden assessment [36] X X X
Hospital Anxiety and Depression Scale [37] X X X
HD recovery time [38] X X X
Qualitative interview At completion or drop out
Dialysis temperature recording During each HD session
Physiological measurements* During each HD session
Laboratory measurements** Measured monthly as part of routine care
Adverse event reporting X X X
Review Concomitant Medications X X X
MoCA Montreal Cognitive Assessment tool, CAM Confusion Assessment Method, QoL quality of life, ADL activities of daily living, HADS Hospital Anxiety and
Depression Scale
*Blood pressure (pre and post HD), intradialytic hypotension, nursing interventions for intradialytic hypotension, intradialytic weight gain over preceding 1 month
**KT/V as markers of adequate solute clearance, routine haematology and biochemistry
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previous setting. This ensures a minimum between-group
temperature separation of 0.5 °C for the expectedly few
intervention group patients who can only tolerate dialysate
temperature reduction to 36 °C. In a previous similarly de-
signed study, only 2 of 73 participants required this proto-
col deviation [28].
Blinding
This study design allows double blinding of both pa-
tients and investigators. All outcomes are measured at 0
(baseline), 6 and 12 months by a blinded rater, on a non-
dialysis day when the best performance is expected [16,
17]. Blinding of the rater could be compromised if the
rater visited the patient during HD as machine settings
might be visible. Testing patients shortly before a HD
treatment might be inconvenient with implications for
recruitment and retention. Therefore, in this study, all
assessments are conducted in domiciliary visits in the
homes of patients or a mutually agreed venue. The carer
assessment will also be taken at months 0, 6 and 12 by a
blinded independent rater. The only person for whom
blinding will not be practical is the clinical nursing staff
in the haemodialysis unit setting the temperature of the
machine based on the patient’s allocation. However,
these staff will have no contact regarding the
temperature settings with either patients or investigators
performing the assessments regarding the temperature
settings.
Assessment and data collection
Data collection
The data collection schedule is summarised in Table 1.
Once a participant has given valid informed consent,
there will be three study visits at baseline, 6 and 12
months. Data collected will include baseline demograph-
ics. The research team are committed to inclusion. Local
audit data showed that after English, Urdu and Bengali
are the two most used native languages. Whilst inclusion
criteria include a good command of English language,
we will ensure where possible assessments are available
in Urdu and Bengali.
Qualitative data and quantitative data to inform future
trial design
The main aim of the qualitative component is to assess
issues related to patient recruitment. This will include
practicalities of implementing cooler dialysate, adher-
ence to treatment, effectiveness of blindness process and
identification of factors that may affect routine practice
of treatment in various centres. We will apply thematic
analysis to qualitative data collected from semi-
structured interviews.
Tolerability of low temperature
Patients are asked about their ability to tolerate the low
temperature and their level of comfort. They are also
asked whether they need any extra support. The ques-
tionnaire was locally designed and used in an unpub-
lished pilot study where it showed face validity and
reliability.
Confusion Assessment Method (CAM)
The Confusion Assessment method (CAM) is a valid
tool that is brief to administer and excludes the effect of
delirium on cognitive performance [33]. The CAM will
be used to exclude delirium before each study visit and
only if it indicates delirium would assessments be post-
poned by 2 weeks or as directed by the treating clinician.
Montreal Cognitive Assessment (MoCA)
The MoCA is a 30-point brief test of global cognitive
function taking approximately 10 min to administer [31].
There are three alternate English language forms de-
signed to minimise practice effects in longitudinal stud-
ies. The MoCA is included as the planned primary
outcome in a future definitively powered clinical trial. A
prior study validated the German language version of
the MoCA in HD patients against a detailed neuro-
psychological battery of cognitive tests [42]. To our
knowledge, this study will provide the first English lan-
guage validation of the MoCA in HD patients against
the Cogstate a detailed assessment of cognitive function.
The MoCA is also available in Urdu and Bengali lan-
guage, the two most common non-English native lan-
guages used by participants in the research sites.
Cogstate
The Cogstate system is a well validated computerised
test that assesses a diverse range of key cognitive skills
[32]. The Cogstate is available in 90 languages and uses
multiple ‘parallel’ versions of the tests, thus minimising
practice effects. The use of reliable repeated measures is
of particular utility in studies in which participants may
not be blind to their treatment status. The Cogstate sys-
tem was also selected to reduce test fatigue and simplify
test administration, whilst preserving strong test-retest
reliability (rho = 0.81–0.89). It has the advantages of be-
ing portable, short (20–30min), game-like in presenta-
tion and thus motivating, cross-culturally adaptable and
language independent.
Quality of life
We will use the Assessment of Quality of Life (AQoL-
6D) scale to measure patient’s quality of life [34]. This is
a generic health-related quality of life instrument, which
provides a profile relative to four life dimensions. Ad-
ministration typically takes 5 to 10min.
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Activities of daily living
The Bristol Activity of Daily Living Scale will be used to
measure activities of daily living in relation to cognitive
impairment [35]. This is an informant-rated interview of
20 items each rated on 60-point scale. It was designed
for use in patients with cognitive impairment.
Anxiety and depressive symptoms
The Hospital Anxiety and Depression Scale is a valid
measure of anxiety and depression in patients with fre-
quent hospital admissions where higher scores reflect
greater depression and anxiety [37]. Systematic review
identified a threshold score of 8 out of 21 for anxiety or
depression [43] and 15 out of 21 as appropriate to refer
patients into mental health care pathways.
Carer burden assessment
We will measure carer burden using Caregiver Burden
scale, which was developed to assess perceived burden
among caregivers of family members with cognitive im-
pairment [36].
Physiological measurements
Intradialytic hypotension
Intradialytic hypotension is an important secondary out-
come for this trial as reducing these episodes are a
plausible mechanism by which dialysate cooling might
prevent cognitive decline. Intradialytic hypotension has
been defined in several ways in prior studies making
comparisons challenging. Symptoms are also infre-
quently self-reported by patients making symptom-based
definitions problematic [44]. Recent data demonstrates
that brain ischemia can occur at a variety of thresholds
that would not typically be recognised as intradialytic
hypotension [45]. A recent 77 patient study reported sys-
tolic blood pressure (BP) less than 100 mmHg or a 20%
reduction in systolic BP from baseline as thresholds that
maximised the probability of a nursing intervention ra-
ther than a session remaining asymptomatic [44]. Au-
thors of a study of 11,801 HD patients reported that
intradialytic hypotension defined as systolic BP less than
90mmHg was potently associated with greater mortality
[12] whilst definitions based on patient symptoms, nurs-
ing interventions or relative decreases in BP during dia-
lysis were not. For this study, BP will be recorded as in
routine clinical practice, before start and after end of
dialysis session. In addition, BP will be checked every 30
min during HD treatment. For analysis, intradialytic
hypotension will be defined as a fall in systolic BP during
dialysis greater than 20% from baseline or absolute sys-
tolic BP less than 90 mmHg. Nursing interventions for
intradialytic hypotension (slowing down ultrafiltration,
giving additional fluid) are routinely recorded.
Intradialytic weight gain, ultrafiltration volume and
ultrafiltration rate
Weight gain between dialysis sessions, the volume of
fluid removed per treatment session (ultrafiltration vol-
ume) and the rate at which it is removed (ultrafiltration
rate) will be extracted from routinely recorded HD treat-
ment records and transferred monthly into the case re-
port form by research staff after verification for any
missing or implausible values. The feasibility of this
process will be reported.
HD recovery time
The HD recovery time will be recorded by a simple
question, “How long does it take you to recover from a
dialysis session”. A mean of 3 reported recovery times
across a dialysis week (Monday, Wednesday and Friday
or Tuesday, Thursday and Saturday) will be assessed at
baseline, 6 months and 12 months. Longer self-reported
recovery time is independently associated with reduced
health-related quality of life, increased hospitalisation
and reduced survivals [38].
Adherence to treatment allocation
Adherence to the allocated dialysate temperature will be
regularly checked and recorded by research staff at each
research site using electronic records which enable dis-
tinction between prescribed and delivered dialysate
temperature. Analysis would be by intention to treat.
Outcome measures
Primary outcome measure
The primary outcome measure is change in cognition
from baseline to 12months, assessed by Montreal Cog-
nitive Assessment (MoCA, v7.2) [31], in the standard
and low temperature dialysis groups.
Secondary outcome measures
1. Frequency of intradialytic hypotension: to measure
the frequency of intradialytic hypotension as an
explanatory outcome
2. Recruitment rates: to measure recruitment to
inform the design of a larger clinical trial
3. Attrition rates: to measure attrition rates to inform
the design of a larger clinical trial
4. Non-recruitment reasons: to record reasons for
non-recruitment and study attrition to inform the
design of a larger clinical trial.
5. Depression rates: to measure depressive symptoms
in the targeted population using the Hospital
Anxiety and Depression Scale (HADS) [37].
6. Detailed assessment of cognition: to assess the
acceptability and usability of a computerised
cognitive assessment method (Cogstate) [32] for
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measuring cognition in dialysis patients, especially
those from ethnic minorities. The Cogstate battery
contains measures attention, psychomotor function,
executive function and memory. The main outcome
for this set of tests will be a composite cognitive score
7. To assess the burden of study-related interventions and
assessments on carers using the Bristol Activities of
Daily living scale and Carers Burden Assessment [36].
8. To assess the administration and suitability of the
chosen method for measuring carers’ burden in this
group.
9. To assess quality of life and activities of daily living
in participants using the Assessment of Quality of
Life (AQoL-6D) questionnaire [34].
Data analysis
Data analysis will be performed by statisticians who are
blinded to participant treatment allocation. A mixed
method approach will be used, utilising semi-structured
interviews, questionnaires and measurement of cognitive
function. The 12month follow-up period will be the key
assessment time for all outcomes. Normally distributed
data will be presented as mean (SD), skewed data as me-
dian (IQR) and categorical data as number (percent).
The main aim of the qualitative component is to assess
issues related to patient recruitment. This will include
practicalities of implementing cooler dialysate, adherence
to treatment, effectiveness of blindness process and identi-
fication of factors that may affect routine practice of treat-
ment in various centres. We will apply thematic analysis
to qualitative data collected from semi-structured inter-
views. Interviews will be on a 1:1 basis and will be audio-
recorded. They will be transcribed by the research assist-
ant and will be anonymised and securely stored, accessible
only by the research team. The purpose of the quantitative
analysis is to estimate the mean and standard deviation
for MoCA at baseline and follow-up in both trial arms
and obtain an estimate of the attrition. For all analysis, the
level of significance will be set at 5%, so that 95% confi-
dence intervals will be presented. This is a feasibility study
and statistically or clinically significant changes in out-
comes between groups are unlikely; hence, no between-
group inferential comparisons will be made. However, a
preliminary estimate of a treatment effect is relevant to
sample size estimation of future definitive trials. As an ex-
ploratory analysis, we will conduct a complete case ana-
lysis of the primary and secondary outcomes. A linear
regression model will be used for continuous outcomes
(e.g. MoCA) and a logistic regression model will be used
for binary outcomes. Each model will include the baseline
measurement and treatment arm as independent vari-
ables. All patients randomised to their respective study
arms will be included in the intention to treat analysis.
Missing data, if any, will be managed using the last-
observation carried forward approach. There will be no in-
terim analysis of the data, though the safety data resulting
from any SAE will be collated and made available to the
Trial Steering Committee. All analysis will be conducted
in Stata 15.
Sample size
The outcome data from this feasibility study will be used
to inform the sample size calculation for the definitive
trial, by providing estimates of the primary outcome and
its variability and the expected attrition. The study aims to
recruit a total of 90 patients from four sites. Lancaster and
co-workers outlined the key aspects of feasibility studies
and indicated at least 30 patients per each arm are re-
quired to identify the sample variability (standard devi-
ation) in key variables to enable the calculation of power
for testing hypotheses in subsequent definitive studies
[46]. The primary outcome in the definitive study is likely
to be a value from the MoCA. With 45 patients in each
arm, and if the mean (SD) value of the MoCA is 27 (2) in
the control and intervention arms at the study start, we
could expect a 95% confidence interval to range from 26.4
to 27.6 in each arm. This will give adequate precision for
the estimate required in the study. With 45 patients in the
control arm, and assuming a mean (SD) value of MoCA of
22 (3) after 12months, we could expect a 95% confidence
interval to range from 21.1 to 22.9. In the intervention
arm, assuming a mean (SD) MoCA value of 25 (3) after
12months, we could expect a 95% confidence interval to
range from 24.1 to 25.9. Furthermore, with a total sample
size of 90 patients, with an expected loss of 20% of the pa-
tients, a 95% confidence interval could be produced, ran-
ging from 70.2 to 87.7%.
Ethics
Ethical approval for trial has been obtained from the Na-
tional Research Ethics Service Committee West
Midlands-South Birmingham IRAS ID 234107 for all
participating centres prior to study initiation and patient
enrolment. The study will be performed in accordance
with the Research Governance Framework, International
Conference on Harmonisation Good Clinical Practice
Guideline and the 2000 Scotland Revision of the Declar-
ation of Helsinki. All participants are to provide written
informed consent before any trial related procedure can
occur. The University Hospitals Birmingham NHS Foun-
dation Trust will provide trial oversight as the trial
sponsor.
Data management
All participants are assigned unique study numbers to
ensure data is recorded in an anonymised fashion. All
study documents are securely stored and only accessible
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to study staff and authorised personnel. All essential data
transfer will happen within the secure networks.
Study management
The study is monitored and audited by University Hos-
pitals Birmingham NHS Foundation Trust under their
remit as Sponsor and other regulatory bodies to ensure
adherence to Good Clinical Practice and the UK Policy
Framework for Health and Social Care Research. Univer-
sity Hospitals Birmingham NHS Foundation Trust holds
standard NHS Hospital indemnity and insurance cover
with NHS Litigation Authority for NHS Trusts in Eng-
land, which apply to this study. The trial management
committee (TMC) will meet at least quarterly during the
duration of the study. They will provide guidance on the
day to day running of the study, review study aims and
ensure they are being met; they will report into the Trial
Steering Committee (TSC). The TSC will be independ-
ent from the TMC, except for a sponsor representative.
The TSC will meet at least every 6months to review
study data and offer guidance on the study outcomes
and further direction of the potential full study. Supple-
mentary Table 1 provides description of the roles for the
study groups that are involved in the oversight and man-
agement/auditing of the trial.
Protocol amendments
If any amendments to the study are required, the amend-
ment will be agreed by the TMC and approved by the
Sponsor. The appropriate approvals from the relevant
regulatory authorities will be obtained and once received
the amendment will be implemented. A full audit trail of
the amendment will be contained in the Trial Master File.
Harms
Serious adverse events (SAEs) will be reported using
SAE reporting forms in the patient’s case report form.
The principal investigator in each centre must report
any SAEs to the Trial Co-ordinating Centre within 24 h
of them becoming aware of it. The trial co-ordinator will
liaise with the investigator to compile all the necessary
information. The Trial Co-ordinating Centre is respon-
sible for reporting adverse events to the sponsor and
ethics committee within required timelines.
Dissemination
The results from this study will be important for the kid-
ney care community. The findings will be presented at
national and international nephrology meetings. It is an-
ticipated that this study will produce manuscripts suit-
able for submission to relevant peer-reviewed journals.
The intention is to ensure all publications are open to
access to encourage widespread dissemination of our
findings.
Patient and public involvement
Service users were important in designing the project and
remain involved in its ongoing management. A service
user representative is both a co-investigator and co-author
to this research protocol and a service user group has led
on key decisions around the frequency, setting and timing
of assessments. Service users also helped write plain Eng-
lish summaries and gave feedback on the draft patient in-
formation sheets. Provision in the study design for use of
language translators was led by service user. There is
funding in the grant and local charitable funds will ensure
the ongoing involvement of service users. Service users
will also be invited to an end of study research event to
share the results and future steps.
Supplementary Table S1 provides all of the items from
the WHO trial registry. More details can be found
within the body of the protocol in Additional file 4.
Discussion
This feasibility trial is designed to inform the develop-
ment of a definitive, fully powered, randomised, con-
trolled clinical trial in the future. The main hypothesis
that would be tested in this future trial is that patients
treated with regular conventional haemodialysis will
have a lesser decline in cognitive function and a better
quality of life over one year by using cooler dialysis fluid
at 35 °C, versus a standard dialysis fluid temperature of
36.5 °C. This also should reflect in improvements in their
abilities for activities of daily living and therefore reduce
carers’ burden. If successful, the treatment could be uni-
versally applied at no extra cost.
The main strengths of this study are (a) this is the first
trial to assess the effect of cool dialysate temperature on
cognitive function and quality of life for HD patients and
carers, (b) the prospective multi-site, randomised, double-
blinded, controlled trial design and (c) a range of out-
comes will be assessed to inform study design of a future
larger trial. This study will also allow validation of MOCA
against a battery of computerised neuro-cognitive tests
(Cogstate) in haemodialysis patients. The limitations of
the study include patients requiring a good command of
spoken English which may exclude those from an ethnic
background and hence results may not be representative.
Also, no comparisons will be made to other forms of renal
replacement therapy (renal transplant and peritoneal dia-
lysis) in terms of change in cognitive function.
One of the main practical issues we anticipate is diffi-
culty in maintaining blinding of dialysate temperature to
the patient, especially to patients who set up their own
machines. Also, symptoms related to low temperature
dialysis, feeling cold in the main, may also give it away.
Secondly, recording BP every 30 min during HD treat-
ment (lasting 4 h, 3 times a week) for 12 months may
also prove challenging as this is not a routine practice in
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most dialysis centres in the UK; more so because these
will be recorded by clinical nurses rather than research
nurses. The third issue, which we think may make re-
cruitment difficult, is the necessity for the patient to at-
tend research appointments on a non-dialysis day.
Although they will need to attend only 3 times over 12-
month period, haemodialysis patients are generally not
keen to attend hospital appointments outside their dialy-
sis sessions. However, how these issues are dealt with
during conduct of this study will help inform the design
of the future substantive trial.
Supplementary Table S1 provides all of the items from
the WHO trial registry. More details can be found
within the body of the protocol in Additional file 4.
Trial status
Protocol version 2.16, dated 21 June 2018
Date recruitment began: 20 December 2017
Approximate date the recruitment will be completed:
31 October 2020
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-020-04725-0.
Additional file 1. Patient Information pack.
Additional file 2. Consent Form.
Additional file 3: Supplementary Table S1- WHO Trial registry
dataset.
Additional file 4.
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